•Time trends of pediatric inflammatory bowel disease in Catalonia from 2011 to 2023. Population-based cohort study
•Campylobacter spp. infection and subsequent clinical outcomes in patients with inflammatory bowel disease
•Probiotic-Derived Extracellular Vesicles as Potential Nano-Immunotherapeutic Platforms in IBD: A Clinician's Perspective
•Long-term real-world effectiveness and safety of mirikizumab in ulcerative colitis: 52-Week results from an expanded international two-center retrospective cohort study
•A novel Bacillus megaterium/ω-3 PUFA synbiotic attenuates colon inflammation and promotes a pro-resolving macrophage profile ex-vivo